Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer
(Final Recommendation Issued as of March 24, 2020)

Daratumumab (Darzalex) for Multiple Myeloma 
Notification to Implement Issued as of March 20, 2020)

Pembrolizumab (Keytruda) for Head and Neck Squamous Cell Carcinoma
(Pending Submission as of March 19, 2020)

Venetoclax (Venclexta) in Combination with Obinutuzumab for Chronic Lymphocytic Leukemia
(Pending Submission as of March 19, 2020)

Acalabrutinib (Calquence) for Chronic Lymphocytic Leukemia
(Pending Submission as of March 6, 2020)

Acalabrutinib (Calquence) for Chronic Lymphocytic Leukemia (previously untreated)
(Pending Submission as of March 6, 2020)

Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma in Combination with Doxorubicin, Vinblastine, and Dacarbazine
Pending Submission as of March 5, 2020)

Brentuximab Vedotin (Adcetris) for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides
(Pending Submission as of March 2, 2020)

Find a Drug Review